|
|
|
Volumn 14, Issue 77, 2005, Pages 115-
|
|
How to avoid future Vioxxo-type scandals
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
CYCLOOXYGENASE 2 INHIBITOR;
IBUPROFEN;
NAPROXEN;
NONSTEROID ANTIINFLAMMATORY AGENT;
PARACETAMOL;
PLACEBO;
ROFECOXIB;
CARDIOVASCULAR RISK;
CLINICAL TRIAL;
DRUG APPROVAL;
DRUG INFORMATION;
DRUG MARKETING;
DRUG SAFETY;
DRUG WITHDRAWAL;
GASTROINTESTINAL SYMPTOM;
HEALTH INSURANCE;
HEART INFARCTION;
HUMAN;
HYPERTENSION;
NOTE;
OSTEOARTHRITIS;
POSTMARKETING SURVEILLANCE;
REIMBURSEMENT;
RHEUMATOID ARTHRITIS;
SUDDEN DEATH;
CARDIOVASCULAR DISEASES;
CLINICAL TRIALS;
CONFLICT OF INTEREST;
DISCLOSURE;
DRUG APPROVAL;
DRUG INDUSTRY;
FRANCE;
GOVERNMENT REGULATION;
HUMANS;
JOURNALISM;
LACTONES;
OSTEOARTHRITIS;
PRODUCT SURVEILLANCE, POSTMARKETING;
SULFONES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 20344382486
PISSN: 11677422
EISSN: None
Source Type: Journal
DOI: None Document Type: Note |
|
Times cited : (11)
|
|
References (0)
|